EUVIMEDEUVIMED entdecken
Crossref

Kamebakaurin Suppresses Antigen-Induced Mast Cell Activation by Inhibition of FcεRI Signaling Pathway

Haruka Asai, Koichi Kato, Mayu Miyasaka, Kaho Hatsukawa, Nanami Murakami, Naoko Takeda, Junna Abe, Yutaka Aoyagi, Yuka Kohda, Ming-Yu Gui, Yong-Ri Jin, Xu-Wen Li und 5 weitere

International Archives of Allergy and Immunology · 2024

DOI: 10.1159/000536334 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2024. Verfasst von Haruka Asai und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan, asai-h@kinjo-u.ac.jp. Hauptthemen laut MEDLINE: Mast Cells, Receptors, IgE, Signal Transduction, Cell Degranulation. Die Arbeit nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Kamebakaurin is an active constituent of both Rabdosia japonica and Rabdosia excisa, which are utilized in Chinese traditional medicine for improving symptoms in patients with allergies. We investigated the molecular mechanisms of the anti-allergic effects of kamebakaurin using BMMCs.

Methods

The degranulation ratio, histamine release, and the interleukin (IL)-4, leukotriene B4 (LTB4), and cysteinyl leukotriene productions on antigen-triggered BMMC were investigated. Additionally, the effects of kamebakaurin on signal transduction proteins were examined by Western blot and binding to the Syk and Lyn kinase domain was calculated. The effects of kamebakaurin on antigen-induced hyperpermeability were investigated using mouse model.

Results

At 10 μm, kamebakaurin partially inhibited degranulation, histamine release, and IL-4 production. At 30 μm, kamebakaurin partially reduced LTB4 and cysteinyl leukotriene productions and suppressed degranulation, histamine release, and IL-4 production. Phosphorylation of both Syk Y519/520 and its downstream protein, Gab2, was reduced by kamebakaurin, and complete inhibition was observed with 30 μm kamebakaurin. In contrast, phosphorylation of Erk was only partially inhibited, even in the presence of 30 μm kamebakaurin. Syk Y519/520 is known to be auto-phosphorylated via intramolecular ATP present in its own ATP-binding site, and this auto-phosphorylation triggers degranulation, histamine release, and IL-4 production. Docking simulation study indicated kamebakaurin blocked ATP binding to the ATP-binding site in Syk. Therefore, inhibition of Syk auto-phosphorylation by kamebakaurin binding to the Syk ATP-binding site appeared to cause a reduction of histamine release and IL-4 production. Kamebakaurin inhibited antigen-induced vascular hyperpermeability in a dose-dependent fashion but did not reduce histamine-induced vascular hyperpermeability.

Conclusion

Kamebakaurin ameliorates allergic symptoms via inhibition of Syk phosphorylation; thus, kamebakaurin could be a lead compound for the new anti-allergic drug.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mast CellsReceptors, IgESignal TransductionCell DegranulationSyk KinaseAnimalsMiceInterleukin-4Histamine ReleaseAntigensAnti-Allergic AgentsMice, Inbred BALB CPhosphorylationHypersensitivity

Stichwörter der Autor:innen

AllergyInflammationKamebakaurinMast cellsSpleen tyrosine kinase

Substanzen

Receptors, IgESyk KinaseInterleukin-4AntigensAnti-Allergic Agents

Autor:innen und Institutionen

  • Department of Pharmacology, College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan, asai-h@kinjo-u.ac.jp.
  • Department of Pharmacotherapeutics, Faculty of Pharmaceutical Sciences, Shonan University of Medical Sciences, Yokohama, Japan.
  • Department of Pharmacology, College of Pharmacy, Kinjo Gakuin University, Nagoya, Japan.
  • Department of Pharmacognosy, Graduate School of Pharmaceutical Sciences, Kinjo Gakuin University, Nagoya, Japan.
  • Department of Pharmacotherapeutics, Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, Osaka, Japan.
  • Department of Chemistry, Jilin University, Jilin, China.

Zitieren

APA

Asai, H., Kato, K., Miyasaka, M., Hatsukawa, K., Murakami, N., Takeda, N., Abe, J., Aoyagi, Y., Kohda, Y., Gui, M. Y., Jin, Y. R., Li, X. W., Hitotsuyanagi, Y., Takeya, K., Andoh, T., Kurosaki, H., & Fukuishi, N. (2024). Kamebakaurin Suppresses Antigen-Induced Mast Cell Activation by Inhibition of FcεRI Signaling Pathway. International Archives of Allergy and Immunology. https://doi.org/10.1159/000536334

Vancouver

Asai H, Kato K, Miyasaka M, Hatsukawa K, Murakami N, Takeda N, et al. Kamebakaurin Suppresses Antigen-Induced Mast Cell Activation by Inhibition of FcεRI Signaling Pathway. International Archives of Allergy and Immunology. 2024. doi:10.1159/000536334

BibTeX
@article{Asai2024,
  author = {Asai, Haruka and Kato, Koichi and Miyasaka, Mayu and Hatsukawa, Kaho and Murakami, Nanami and Takeda, Naoko and Abe, Junna and Aoyagi, Yutaka and Kohda, Yuka and Gui, Ming-Yu and Jin, Yong-Ri and Li, Xu-Wen and Hitotsuyanagi, Yukio and Takeya, Koichi and Andoh, Tsugunobu and Kurosaki, Hiromasa and Fukuishi, Nobuyuki},
  title = {Kamebakaurin Suppresses Antigen-Induced Mast Cell Activation by Inhibition of FcεRI Signaling Pathway},
  journal = {International Archives of Allergy and Immunology},
  year = {2024},
  doi = {10.1159/000536334}
}
Kostenlos starten →